Sequential combinations of flavopiridol and docetaxel inhibit prostate tumors, induce apoptosis, and decrease angiogenesis in the Gγ/T-15 transgenic house model of prostate cancer

Teresita Reiner, Alicia De Las Pozas, Carlos Perez-Stable

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

BACKGROUND. We investigated whether sequential combinations of flavopiridol and docetaxel can increase apoptotic cell death and inhibit the growth of primary and metastatic prostate tumors in the Gγ/T-15 transgenic mouse model of prostate cancer. METHODS. Transgenic males were treated and the weights of primary and metastatic prostate tumors determined. Immunohistochemistry and Western blot was performed to evaluate the differences in apoptosis, proliferation, and angiogenesis. RESULTS. Docetaxel was slightly more effective than flavopiridol in inhibiting primary prostate tumors, but neither drug alone inhibited metastases. Single drug treatments decreased angiogenesis but did not increase apoptosis. Both sequential combinations resulted in greater inhibition of primary and metastatic prostate tumors, increased apoptosis, and decreased angiogenesis compared to control mice. CONCLUSIONS. Flavopiridol and docetaxel sequence combinations were effective in inhibiting prostate tumors in the Gγ/T-15 transgenic mice. An increase in apoptosis and a decrease in angiogenesis resulted in the greatest inhibition of prostate cancers.

Original languageEnglish (US)
Pages (from-to)1487-1497
Number of pages11
JournalProstate
Volume66
Issue number14
DOIs
StatePublished - Oct 1 2006

Keywords

  • Angiogenesis
  • Apoptosis
  • Metastases
  • Prostate cancer
  • Transgenic mice

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Sequential combinations of flavopiridol and docetaxel inhibit prostate tumors, induce apoptosis, and decrease angiogenesis in the Gγ/T-15 transgenic house model of prostate cancer'. Together they form a unique fingerprint.

Cite this